New education campaign launched as part of Lilly-Boehringer diabetes alliance

A new diabetes education initiative has been launched to help improve people’s understanding of the role sodium glucose co-transporters (SGLT) play in maintaining blood sugar balance in people with type 2 diabetes.
The joint campaign by pharmaceutical giants Boehringer Ingelheim and Eli Lilly is designed to educate healthcare professionals on how SGLTs (sodium-dependent glucose transport proteins) enable the kidneys to reabsorb glucose and prevent it being passed out of the body in the urine.
Christophe Arbet-Engels, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim, explains: “The contribution of insulin resistance and impaired beta cell function in the physiopathology of type 2 diabetes mellitus has been extensively studied.
“The contributing role of persistently high glucose levels in the progression of type 2 diabetes has led to the need for a better understanding of how glucose is reabsorbed by the kidneys.
“The Boehringer Ingelheim and Lilly Diabetes alliance is very pleased to offer healthcare professionals an educational resource they can use at their convenience to gain greater knowledge of this process.”
The new initiative includes a microsite (sglt.com), which features a short educational video created by the London-based Royal Society for the encouragement of Arts, Manufacturing and Commerce (RSA). Viewers are invited to sign up for further learning resources that will be offered throughout the year.